AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11429668
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) used alone or in combination with other antibiotics
Trial: 11429668
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with a proton pump inhibitor, clarithromycin and either amoxicillin or a nitroimidazole (tinidazole or metronidazole)
Trial: 11429668
Drug: Analogous regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analogous regimens with RBC in place of proton pump inhibitors
Trial: 9099655
Drug: Combination diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination diet rich in fruits, vegetables, and low-fat dairy products
Trial: 9099655
Drug: Combination diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination diet (hypertensive subjects)
Trial: 9099655
Drug: Combination diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination diet (non-hypertensive subjects)
Trial: 2854762
Drug: Naloxone (NAL)
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone (NAL) infusion (5 mg bolus + 2.1 mg/h for 7 h)
Trial: 2854762
Drug: Tamoxifen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (10 mg twice daily for 6 weeks)
Trial: 2854762
Drug: Naloxone (NAL)
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone (NAL) infusion after tamoxifen administration
Trial: 30111294
Drug: Ondansetron 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.05 mg/kg (group O1)
Trial: 30111294
Drug: Ondansetron 0.1
RxNorm normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.1 mg/kg (group O2)
Trial: 27625082
Drug: Olmesartan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (20 mg per day)
Trial: 25547319
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education program (DVD)
Trial: 9576425
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 to 40 mg once daily
Trial: 7872726
Drug: High-dose gestagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose gestagen treatment (500 mg MPA i.m. twice weekly for three months)
Trial: 3124432
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dosage of cytosine arabinoside (3mg/m2/twice daily)
Trial: 3124432
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dosage of cytosine arabinoside (3mg/m2/twice daily) with androgens
Trial: 30282393
Drug: Intraarticular methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular methylprednisolone injection
Trial: 26692193
Drug: ACT‐453859 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT‐453859 (400 mg once daily or 100 mg twice daily)
Trial: 26692193
Drug: Setipiprant (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setipiprant (not specified dosage)
Trial: 22421745
Drug: Raltegravir (RAL)
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir (RAL) 400 mg + Atazanavir (ATV) 300 mg twice daily for 4 weeks followed by RAL 800 mg + ATV/ritonavir 300/100 mg once daily for 4 weeks
Trial: 16274368
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (ergocalciferol, initially 10,000 IU weekly then 1,000 IU daily)
Trial: 11354390
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg IR clarithromycin tablets twice daily for 7 days (AECB) or 14 days (AMS)
Trial: 11354390
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg (2 x 500 mg) ER clarithromycin tablets once daily for 7 days (AECB) or 14 days (AMS)
Trial: 3308731
Drug: Buflomedil, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buflomedil, 600 mg daily for 4 weeks
Trial: 28284473
Drug: Positive Expiratory
RxNorm normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive Expiratory Pressure (PEP) therapy
Trial: 25218610
Drug: Oxycodone/Naloxone prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/Naloxone prolonged-release (OXN PR)
Trial: 25218610
Drug: Oxycodone prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone prolonged-release (OxyPR)
Trial: 16955243
Drug: Levocetirizine (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine (1.25 mg, 2.5 mg, 5 mg)
Trial: 16955243
Drug: Desloratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine (10 mg)
Trial: 8514070
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of lidocaine spray
Trial: 29431520
Drug: trans-resveratrol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trans-resveratrol (300 mg)
Trial: 27611858
Drug: DAPA (SGLT2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPA (SGLT2 inhibitor)
Trial: 27611858
Drug: DAPA (SGLT2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPA (SGLT2 inhibitor) + PPAR-γ inhibitor GW9662
Trial: 25281710
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2 i.v. on day 1 of a 21-day cycle)
Trial: 12472787
Drug: Progression from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progression from macroalbuminuria to elevated plasma creatinine or renal replacement therapy (RRT)
Trial: 10224345
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g) given intravenously at the induction of anesthesia
Trial: 10224345
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g) given intravenously at the induction of anesthesia
Trial: 6349538
Drug: Lentinan (LNT)
RxNorm normalized name: lentinan
DrugBank: Lentinan (DB13480)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentinan (LNT) administered intravenously at doses of 1 mg/person/day twice a week or 2 mg/person/day once a week in combination with mitomycin C + 5-FU (MF) or tegafur (FT)
Trial: 6349538
Drug: Control therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy: MF or FT alone
Trial: 6349538
Drug: Lentinan (LNT)
RxNorm normalized name: lentinan
DrugBank: Lentinan (DB13480)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentinan (LNT) as supportive therapy for advanced or recurrent breast cancer
Trial: 31794512
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's wort (300 mg thrice daily)
Trial: 28682677
Drug: Polyhexanide/betaine gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyhexanide/betaine gel
Trial: 25079928
Drug: Continuous ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous ranibizumab (0.5 mg monthly)
Trial: 25079928
Drug: Discontinuous ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Discontinuous ranibizumab (0.5 mg as-needed)
Trial: 25079928
Drug: Continuous bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous bevacizumab (1.25 mg monthly)
Trial: 25079928
Drug: Discontinuous bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Discontinuous bevacizumab (1.25 mg as-needed)
Trial: 19531929
Drug: Intermittent ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent ART (drug conservation group; DC)
Trial: 15465622
Drug: Double-immunofluorescence using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-immunofluorescence using Abeta antibodies
Trial: 11204435
Drug: Osteoprotegerin (OPG)
RxNorm normalized name: Osteoprotegerin recombinant
DrugBank: AMGN-0007 (DB06511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteoprotegerin (OPG) 3.0 mg/kg
Trial: 9435420
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor-I (IGF-I) at 5 micrograms/kg/h in a continuous s.c. infusion
Trial: 9435420
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) at 0.03 IU/kg/daily s.c. injection
Trial: 7905730
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interferon gamma (0.1 mg subcutaneously for 10 days)
Trial: 31676145
Drug: ≥60 mL/kg/24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≥60 mL/kg/24 h
Trial: 31676145
Drug: <60 mL/kg/24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <60 mL/kg/24 h
Trial: 22286628
Drug: Intermittent sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent sequential compression (ISC) of legs
Trial: 10964334
Drug: Doxil 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil 35 mg/m2 every 3 weeks
Trial: 10789595
Drug: Doxil 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil 45 mg/m2 every 3 weeks
Trial: 10964334
Drug: Doxil 50
RxNorm normalized name: Doxil 50 MG in 25 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil 50 mg/m2 every 4 weeks
Trial: 10789595
Drug: Doxil 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil 60 mg/m2 every 4 weeks
Trial: 10964334
Drug: Doxil 65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil 65 mg/m2 every 5 weeks
Trial: 10964334
Drug: Doxil 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil 70 mg/m2 every 6 weeks
Trial: 10964334
Drug: Doxil (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil (various doses)
Trial: 1463155
Drug: Enoximone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 1.25 mg/kg
Trial: 19108662
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) at varying doses (placebo, 0.15 mg/kg t.i.d., 0.3 mg/kg t.i.d., and 0.6 mg/kg t.i.d.) combined with behavior modification therapy (BMOD) at three intensities (no, low, high) for 3 weeks each.
Trial: 19108662
Drug: Behavior modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior modification therapy (BMOD) at three intensities (no, low, high) for 3 weeks each.
Trial: 14622664
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine sulfate delivery system
Trial: 10831478
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR (75, 150, or 225 mg/day)
Trial: 9335387
Drug: 1.0 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mmol/L dialysate calcium
Trial: 9335387
Drug: 1.25 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mmol/L dialysate calcium
Trial: 8382725
Drug: RRVxDS-1 (serotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRVxDS-1 (serotype 2 vaccine)
Trial: 8382725
Drug: RRVxD (serotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRVxD (serotype 1 vaccine)
Trial: 31813658
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate sodium (PPS) monotherapy for 16 weeks
Trial: 30646043
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning model predicting 30-day mortality from chemotherapy start
Trial: 30646043
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning model predicting 30-day mortality among patients receiving palliative chemotherapy
Trial: 8937963
Drug: Previous use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous use of azole therapy
Trial: 8937963
Drug: More than
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More than five episodes of oral candidosis in the last year
Trial: 2868748
Drug: Fenoldopam 25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam 25, 50, or 100 mg (dose-ranging study)
Trial: 2868748
Drug: Fenoldopam 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam 100 mg (double-blind study)
Trial: 2868748
Drug: Fenoldopam 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam 100 mg (after 1 month of 4 times daily dosing)
Trial: 24858821
Drug: Cloxacillin 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloxacillin 4 g i.v. (intervention group)
Trial: 18439587
Drug: Sequential media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential media system
Trial: 11258691
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) DPI, 100 microg, twice daily
Trial: 11258691
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) DPI, 200 microg, twice daily
Trial: 11258691
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) MDI, 168 microg, twice daily
Trial: 9610859
Drug: Disinfection solution
RxNorm normalized name: ALCOHOL 375 mL in 500 mL EXTRACORPOREAL GEL [yeQuick-dry Hand Disinfection Solution]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disinfection solution
Trial: 22118014
Drug: Immediate non-occlusal
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate non-occlusal implant loading
Trial: 22118014
Drug: Early non-occlusal
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early non-occlusal implant loading
Trial: 30877622
Drug: DFN-02 (sumatriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFN-02 (sumatriptan 10 mg nasal spray)
Trial: 12229137
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine 1.5 mg.kg‐1
Trial: 12229137
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.75 ml.kg‐1
Trial: 9881390
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (L and C)
Trial: 10212082
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (250 microg/puff, two puffs, 12 hourly for 14 days)
Trial: 27687307
Drug: ACF (Adriamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACF (Adriamycin 35 mg/m2, cisplatin 70 mg/m2 i.v. on day 1, fluorouracil 700 mg/m2 continuous infusion for 7 days) every 4 weeks
Trial: 27687307
Drug: DCF (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCF (docetaxel 70 mg/m2, cisplatin 70 mg/m2 i.v. on day 1, fluorouracil 700 mg/m2 continuous infusion for 5 days) every 3 weeks
Trial: 21549403
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (physiotherapy, corticosteroid injections, oral anti-inflammatory analgesics)
Trial: 19140899
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin injection therapy (IIT)
Trial: 2648867
Drug: Desipramine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine 200 mg/day
Trial: 30872263
Drug: Enzalutamide with
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide with androgen-deprivation therapy
Trial: 30872263
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with androgen-deprivation therapy
Trial: 23239133
Drug: Reboxetine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (4 mg/day) + Betahistine (48 mg/day)
Trial: 17704973
Drug: Synthetic antidepressive
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic antidepressive drugs
Trial: 11080605
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy with nutritional approach
Trial: 11080605
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy without nutritional approach
Trial: 972260
Drug: 3% hexachlorophene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% hexachlorophene preparation
Trial: 23743482
Drug: 12-weekly LSC
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-weekly LSC videos
Trial: 23743482
Drug: 12-weekly HIV
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-weekly HIV prevention messages
Trial: 15006431
Drug: Pindolol 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 7.5 mg
Trial: 10885352
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg zinc per day as zinc sulphate, 6 days a week for 6 months)
Trial: 8238640
Drug: Haloperidol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (up to 6 mg/day)
Trial: 8238640
Drug: Phenelzine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenelzine (up to 90 mg/day)
Trial: 3804176
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg bd
Trial: 25748117
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) followed by monthly bacillus Calmette-Guérin (BCG) instillations
Trial: 9669004
Drug: 0.06 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg.kg‐1 rocuronium
Trial: 9659028
Drug: mivacurium 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.02 mg.kg‐1
Trial: 10599663
Drug: 350-mm2 Baerveldt
RxNorm normalized name: allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350-mm2 Baerveldt implant
Trial: 10599663
Drug: 500-mm2 Baerveldt
RxNorm normalized name: allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-mm2 Baerveldt implant
Trial: 3052167
Drug: Propofol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5 mg/kg for induction, followed by 10‐min infusion of an induction dose; maintained with continuous infusion of 0.1 mg/kg per min)
Trial: 3052167
Drug: Etomidate (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (18 mg for induction, followed by 2.4 mg/min for maintenance)
Trial: 31785175
Drug: Responsiveness to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responsiveness to deep inhalation methacholine
Trial: 31785175
Drug: Dose‐response slopes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose‐response slopes from deep inhalation mannitol
Trial: 31785175
Drug: Dose‐response slope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose‐response slope from non‐deep inhalation mannitol
Trial: 31397597
Drug: naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen sodium (440 mg)
Trial: 24019420
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (100000 IU, 6 quarterly doses)
Trial: 22288155
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (600 mg once a day, i.v.)
Trial: 22288155
Drug: Mexidol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexidol (300 mg once a day, i.v.)
Trial: 15288411
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER 150-225 mg
Trial: 26537218
Drug: High PL
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High PL krill oil (3 g/day)
Trial: 26537218
Drug: Low PL
RxNorm normalized name: marshmallow plant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low PL krill oil (1.5 g/day)
Trial: 21168198
Drug: Topotecan 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.25 mg/m2 daily for 5 days every 21 days (regimen I)